reference pricing

reference pricing

(prīs′ĭng)
A method of health care cost control in which the cost of all items in a class of roughly equivalent products or services is reimbursed at a fixed dollar amount. Patients or providers who seek care that is more expensive than the reference price pay additional fees. Those who agree to use standard services are reimbursed in full for the products or services they receive.
References in periodicals archive ?
Nonetheless, the departments of Labor and Health and Human Services said the practice -- known as reference pricing -- could continue.
e OFT said the retailers conrmed their commitment to using genuine reference prices and - without any admission of liability - made changes to their reference pricing practices.
It found "systematic" examples of artificially inflated reference pricing within the industry, through the use of "was" prices formerly charged by the retailer, "after sale" prices that the trader intended to charge in the future, or recommended retail prices (RRPs) set by the manufacturer.
For each country there is, as appropriate, a comprehensive review of drug pricing, reference pricing, controls, policy, regulation and reimbursement systems including influencing factors such as procurement and formulary.
This system of international reference pricing inhibits access to essential pharmaceuticals in underdeveloped countries and decreases pharmaceutical innovation and equitable research and development cost-sharing between developed countries.
The idea behind reference pricing is relatively straightforward.
Pharmaceutical pricing: Procedures for setting prices; use of external reference pricing.
Reference Pricing, BiDil, Tysabri, Medicare Part D, and Vioxx All Impacted the Healthcare Industry in 2005
Pharmaceutical brand teams design their global launch sequencing strategies to mitigate the risks associated with reference pricing, a top challenge at many drug companies, according to a new study by Cutting Edge Information.
New Report from Decision Resources Focuses on the Impact of German Reference Pricing on Statins and the Implications for the Pharmaceutical Industry
Surveyed companies rank reference pricing as most important launch-determining factor, finds Cutting Edge Information study
com/research/v2n8n9/drug_price_cuts_in) has announced the addition of the "Drug Price Cuts in Top Five Countries of Europe - Tougher Reference Pricing Environment and Drug Price Freeze through 2013 Expected to Drive Down Healthcare Costs" report to their offering.